Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00556348

Enrollment

500

Registered

2007-11-12

Start date

2005-11-30

Completion date

2008-11-30

Last updated

2011-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age Related Macular Degeneration

Keywords

bevacizumab, AMD, Complications, Visual acuity, OCt, Age Macular Degeneration

Brief summary

To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab (Avastin, Roche, Rio de Janeiro, Brazil) in patients with choroidal neovascularization secondary to age-related macular degeneration.

Detailed description

We conducted a retrospective study of 500 eyes with choroidal neovascularization secondary to age-related macular degeneration who were treated with at least two (initial and one month after) intravitreal injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. Patients underwent Snellen visual acuity testing, optical coherence tomography (OCT) imaging and ophthalmoscopic examination at baseline and follow-up visits.

Interventions

DRUGbevacizumab

1.25mg

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Age related macular degeneration with Juxtafoveal and Subfoveal CNVM: Recurrent CNVM following PDT and TTT with IVTA. Patient who could not afford PDT, Macugen or Lucentis which is FDA approved. * Myopic CNVM, Idiopathic CNVM, Inflammatory CNVM and other conditions associated with CNVM. * Refractory macular oedema due to vein occlusion, Pseudophakia, Clinically significant macular oedema (CSME) etc. that affects vision and does not respond adequately to usual treatment methods. * Proliferative diabetic retinopathy, non-resolving vitreous haemorrhage with PDR.

Exclusion criteria

* Patients with poor compliance * Patients with uncontrolled diabetes and hypertension or any other medical condition that increase the risk of complications like recent history of Stroke or myocardial infraction (\< one year). (Physician clearance was obtained for all patients). * Patients who had undergone major surgery 28 days before, were excluded from the study and it was also suspended prior to elective surgery.

Design outcomes

Primary

Measure	Time frame
Vision change Anatomical changes (Regression of NVE, CNVM, reduction in macular thickness) Electrophysiological changes (ERG, VEP	—

Secondary

Measure	Time frame
Ocular side effects (infection, RD, IOP rise, cataract)	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026